The associations of endocrine AEs with different immunotherapy regimens*
| Strategy | Drug | N | IC | IC025 | IC975 | ROR | ROR025 | ROR975 |
|---|---|---|---|---|---|---|---|---|
| Total | Total ICIs | 6260 | 2.53 | 2.49 | 2.57 | 6.14 | 5.99 | 6.30 |
| Monotherapy | Anti-PD-1 | 3398 | 2.26 | 2.20 | 2.31 | 4.99 | 4.82 | 5.16 |
| Nivolumab | 2219 | 2.24 | 2.17 | 2.31 | 4.90 | 4.70 | 5.12 | |
| Pembrolizumab | 1175 | 2.29 | 2.19 | 2.39 | 5.07 | 4.78 | 5.38 | |
| Cemiplimab | 4 | 1.60 | −0.31 | 3.50 | 3.07 | 1.13 | 8.32 | |
| Anti-PD-L1 | 269 | 1.68 | 1.48 | 1.88 | 3.26 | 2.89 | 3.68 | |
| Atezolizumab | 175 | 1.54 | 1.29 | 1.79 | 2.95 | 2.54 | 3.43 | |
| Avelumab | 27 | 1.66 | 1.01 | 2.31 | 3.22 | 2.20 | 4.73 | |
| Durvalumab | 67 | 2.07 | 1.66 | 2.47 | 4.31 | 3.37 | 5.49 | |
| Anti-CTLA-4 | 708 | 2.97 | 2.84 | 3.09 | 8.29 | 7.68 | 8.95 | |
| Ipilimumab | 706 | 2.97 | 2.84 | 3.09 | 8.30 | 7.69 | 8.96 | |
| Tremelimumab | 2 | 1.55 | −1.49 | 4.59 | 2.98 | 0.72 | 12.33 | |
| Anti-CTLA-4 vs anti-PD-1 | 708 | 1.68 | 1.55 | 1.83 | ||||
| Anti-CTLA-4 vs anti-PD-L1 | 708 | 2.54 | 2.20 | 2.93 | ||||
| Polytherapy | Polytherapy1 | 64 | 4.41 | 4.00 | 4.83 | 25.60 | 19.44 | 33.71 |
| Polytherapy2 | 1664 | 3.15 | 3.07 | 3.24 | 9.58 | 9.11 | 10.07 | |
| Polytherapy3 | 109 | 4.05 | 3.73 | 4.36 | 18.93 | 15.45 | 23.20 | |
| Polytherapy4 | 27 | 3.96 | 3.31 | 4.61 | 17.68 | 11.67 | 26.78 | |
| Polytherapy vs. Monotherapy | 1864 | 2.00 | 1.89 | 2.11 |
*In Table 2, bold text denotes significant signals. Polytherapy1: Nivolumab+ pembrolizumab+ ipilimumab; Polytherapy2: Nivolumab+ ipilimumab; Polytherapy3: Pembrolizumab+ ipilimumab; Polytherapy4: Durvalumab+ tremelimumab. N: number of records; IC025: the lower end of the 95% confidence interval of IC. IC975: the upper end of the 95% confidence interval of IC. ROR025: the lower end of the 95% confidence interval of ROR. ROR975: the upper end of the 95% confidence interval of IC